ASCO 2017- CheckMate 602 A phase 3 trial of combinations of nivo, elo, pom and dex in RRMM - 101867

Spotlight
Video

ASCO 2017- CheckMate 602 A phase 3 trial of combinations of nivo, elo, pom and dex in RRMM

Loading........
Description: Background: Multiple myeloma (MM) cells may evade immune surveillance by suppressing immune responses through the PD-1 pathway, via upregulation of PD-L1.1Nivolumab (nivo), a PD-1 immune checkpoint inhibitor that blocks PD-L1 interaction and disrupts MM-mediated PD-1 signaling, demonstrated modest activity as monotherapy in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in a phase 1b study.2 Pomalidomide, an immunomodulatory drug (IMiD), may sensitize MM cells to PD-1 blockade, and has shown efficacy with dexamethasone (Pd) for RRMM. Elotuzumab (elo), an anti-SLAMF7 monoclonal antibody, directly activates natural killer cells and facilitates antibody-dependent cell-mediated cytotoxicity. Preclinical work suggests PD-1 blockade may enhance elo efficacy3; thus nivo + Pd + elo may increase clinical benefit.

Author(s): Sagar Lonial, Paul G. Richardson, Donna Ellen Reece, Hesham Mohamed, Suresh Shelat, Jesus San Miguel; Winship Cancer Institute, Atlanta, GA; Dana-Farber Cancer Institute, Boston, MA; Princess Margaret Hospital, Toronto, ON, Canada; Bristol-Myers Squibb, Lawrenceville, NJ; Bristol-Myers Squibb, Princeton, NJ; Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain

Clinical trial information: NCT02726581
Shared By : InternationalMyelomaFoundation
Posted on : 08/15/17
Added : 5 months ago
Category : Multiple Myeloma



Recommended

Nothing found.